FLT3 and acute myeloid leukemia: These data provided the first definitive evidence for the benefit of frontline FLT3 inhibitors in FLT3-mutated AML and led to the Food and Drug Administration (FDA) approval of midostaurin in combination with standard induction and consolidation chemotherapy in adults with newly diagnosed FLT3-mutated AML, although the FDA did not approve its use as maintenance therapy.